



Pfizer Inc.
275 N Field Drive
Lake Forest, IL 60045

Global Established Pharma

July 29, 2016

Notification of Procainamide Hydrochloride Injection, USP Supply Interruption

Dear Valued Customer,

This letter is to inform you of a supply interruption involving our Procainamide Hydrochloride Injection, USP. We anticipate the product to stock out sometime in early August. Pfizer Injectables recognizes the importance of this drug and is making every effort to restock the market. We will update you when additional information becomes available. This disruption has impacted the NDC numbers listed in the table below.

NDC	Description
0409-1902-01	Procainamide Hydrochloride Injection, USP 1000 mg/10 mL (100 mg/mL) Fliptop Vial
0409-1903-01	Procainamide Hydrochloride Injection, USP 1000 mg/2 mL (500 mg/mL) Fliptop Vial
0409-1903-25	Procainamide Hydrochloride Injection, USP 1000 mg/2 mL (500 mg/mL) Fliptop Vial Novaplus

At this time, we are anticipating product availability by Q4 2017. We will continue to provide updates on this supply situation as new information becomes available.

Pfizer Injectables is committed to keeping you informed on supply interruptions so that appropriate contingency plans can be made to help facilitate patient care and safety. Your support is appreciated while we work on restoring our supply of Procainamide Hydrochloride Injection, USP, to the market.

Thank you,

Kim Rouse Wing
Senior Portfolio Manager, Specialty Injectables
Global Established Pharma, North America